A detailed history of Capital International LTD transactions in Grifols Sa stock. As of the latest transaction made, Capital International LTD holds 408,110 shares of GRFS stock, worth $3.2 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
408,110
Previous 408,110 -0.0%
Holding current value
$3.2 Million
Previous $2.57 Million 40.96%
% of portfolio
0.16%
Previous 0.12%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$5.47 - $11.38 $104,192 - $216,766
19,048 Added 4.9%
408,110 $2.73 Million
Q4 2023

Feb 13, 2024

SELL
$7.71 - $11.56 $27,378 - $41,049
-3,551 Reduced 0.9%
389,062 $4.5 Million
Q1 2023

May 15, 2023

BUY
$6.65 - $10.69 $93,844 - $150,857
14,112 Added 3.73%
392,613 $2.89 Million
Q4 2022

Feb 14, 2023

BUY
$5.96 - $8.53 $318,061 - $455,211
53,366 Added 16.41%
378,501 $3.22 Million
Q3 2022

Nov 14, 2022

BUY
$5.95 - $14.3 $356,815 - $857,556
59,969 Added 22.62%
325,135 $2 Million
Q2 2022

Aug 15, 2022

BUY
$10.6 - $13.28 $657,687 - $823,970
62,046 Added 30.55%
265,166 $3.15 Million
Q1 2022

May 16, 2022

SELL
$10.37 - $12.73 $457,151 - $561,189
-44,084 Reduced 17.83%
203,120 $2.37 Million
Q4 2021

Feb 14, 2022

SELL
$10.21 - $15.27 $27,628 - $41,320
-2,706 Reduced 1.08%
247,204 $2.78 Million
Q3 2021

Nov 15, 2021

SELL
$14.07 - $17.3 $31,868 - $39,184
-2,265 Reduced 0.9%
249,910 $3.65 Million
Q2 2021

Aug 16, 2021

BUY
$16.62 - $18.94 $404,879 - $461,397
24,361 Added 10.69%
252,175 $4.38 Million
Q1 2021

May 14, 2021

BUY
$15.15 - $19.78 $233,794 - $305,244
15,432 Added 7.27%
227,814 $3.94 Million
Q4 2020

Feb 16, 2021

BUY
$16.86 - $19.67 $264,870 - $309,015
15,710 Added 7.99%
212,382 $3.92 Million
Q3 2020

Nov 13, 2020

BUY
$15.4 - $20.16 $3.03 Million - $3.96 Million
196,672 New
196,672 $3.41 Million

Others Institutions Holding GRFS

About Grifols SA


  • Ticker GRFS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 678,910,976
  • Market Cap $5.33B
  • Description
  • Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...
More about GRFS
Track This Portfolio

Track Capital International LTD Portfolio

Follow Capital International LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International LTD , based on Form 13F filings with the SEC.

News

Stay updated on Capital International LTD with notifications on news.